
Opinion|Videos|January 3, 2025
Team- and System-Based Approaches to Managing LEMS and Ensuring Access
A panelist discusses how comprehensive care coordination between specialists, proactive adverse effect management, and innovative care models can optimize treatment outcomes for Lambert-Eaton myasthenic syndrome (LEMS) patients, particularly those with dual diagnoses like small cell lung cancer (SCLC), while ensuring both clinical effectiveness and cost-efficiency through managed care strategies.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How can health care teams proactively manage adverse effects associated with treatments like amifampridine?
- How can managed care organizations facilitate timely access to LEMS therapies while ensuring cost-effectiveness?
- What strategies can improve communication and coordination between oncologists, neurologists, and pharmacists in managing dual-diagnosis patients?
- What innovative care models have shown promise in improving outcomes for patients with dual diagnoses like SCLC and LEMS?
Advertisement
Related to this article

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

San Francisco experts say earlier IgA nephropathy and FSGS detection depends on primary care education and care coordinators.

The FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.

Earlier MASH fibrosis detection is more urgent now that treatments exist, and automating FIB-4 in EHRs could help primary care, says Rohit Loomba, MD.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.
Advertisement
Advertisement


